Compare Eni SpA (E) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Sana Biotechnology Inc — how do they compare? Eni SpA trades at $55.14 (market cap $80.32B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Eni SpA is far larger — about 71.1× Sana Biotechnology Inc's market cap, and Eni SpA pays a 4.4% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| E | SANA | |
|---|---|---|
Market Cap | $80.32B | $1.13B |
Sector | Energy | Health |
52-Week High | $57.61 | $5.92 |
52-Week Low | $34.03 | $2.68 |
Enterprise Value | $105.61B | $1.05B |
Dividend Yield | 4.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $54.87, up 2.35% today, with a bullish technical signal from moving averages. The stock shows attractive valuation multiples, including a P/E of 12.5 and P/S of 0.82, while recent earnings have been mixed with Q2 2026 missing estimates despite 21.5% revenue growth. Strong cash flow from operations of $13.33 billion in 2025 supports shareholder returns, including a recently increased share buyback program.
The outlook is cautiously optimistic, with production growth and strategic partnerships offering upside, but commodity price volatility and recent earnings misses present risks. Analyst sentiment is mixed, with a 'Moderate Buy' consensus but a majority of holds, reflecting balanced near-term prospects amid energy market uncertainties.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
